These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36847203)

  • 1. Pharmacokinetics and Safety of Imeglimin in Japanese Patients With Impaired Renal Function.
    Kitamura A; Yumizaki T; Kondo T; Sekino H; Kakuyama H
    J Clin Pharmacol; 2023 Jul; 63(7):807-816. PubMed ID: 36847203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.
    Tomita Y; Hansson E; Mazuir F; Wellhagen GJ; Ooi QX; Mezzalana E; Kitamura A; Nemoto D; Bolze S
    Clin Transl Sci; 2022 Apr; 15(4):1014-1026. PubMed ID: 34962074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.
    Chevalier C; Dubourg J; Bolze S; Fouqueray P
    Clin Pharmacokinet; 2021 Apr; 60(4):485-490. PubMed ID: 33169345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
    Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
    Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
    Ermer J; Corcoran M; Lasseter K; Marbury T; Yan B; Martin PT
    Ther Drug Monit; 2016 Aug; 38(4):546-55. PubMed ID: 26926668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.
    Fouqueray P; Chevalier C; Bolze S
    Clin Drug Investig; 2022 Sep; 42(9):721-732. PubMed ID: 35867199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.
    Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Bello A; Murthy B
    Clin Pharmacokinet; 2022 Oct; 61(10):1405-1416. PubMed ID: 35906349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
    Lasseter KC; Sologuren A; La Noce A; Dilzer SC
    Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-State Pharmacokinetics of Intravenous Hydromorphone in Japanese Patients With Renal Impairment and Cancer Pain.
    Nakatani T; Shiosakai K; Hashimoto T; Shionoya M; Akasaka T; Toyama K; Ishizuka H; Saito Y
    J Palliat Med; 2023 Jun; 26(6):768-775. PubMed ID: 36579915
    [No Abstract]   [Full Text] [Related]  

  • 11. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
    Sidharta PN; Ulč I; Dingemanse J
    Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
    Shaik N; LaBadie RR; Hee B; Chan G
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):241-250. PubMed ID: 33388951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Sarashina A; Ueki K; Sasaki T; Tanaka Y; Koiwai K; Sakamoto W; Woerle HJ; Salsali A; Broedl UC; Macha S
    Clin Ther; 2014 Nov; 36(11):1606-15. PubMed ID: 25199997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment.
    Laille E; Goel S; Mita AC; Gabrail NY; Kelly K; Liu L; Songer S; Beach CL
    Pharmacotherapy; 2014 May; 34(5):440-51. PubMed ID: 24877181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Kondo K
    Clin Ther; 2020 Sep; 42(9):1699-1714. PubMed ID: 32868037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
    Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
    Tayo B; Taylor L; Sahebkar F; Morrison G
    Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of revefenacin in subjects with impaired renal or hepatic function.
    Borin MT; Lo A; Barnes CN; Pendyala S; Bourdet DL
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2305-2318. PubMed ID: 31632000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis.
    Haverty T; Wyatt DJ; Porter KM; Leubitz A; Banks K; Goodyer P; Hu MY
    J Clin Pharmacol; 2021 Jul; 61(7):923-931. PubMed ID: 33355924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.